10 - 11 MARCH Preclinical and Translational Immuno-Oncology

10 - 11 MARCH Immunomodulatory Approaches

10 - 11 MARCH CARs, TILs, TCRs

11 - 12 MARCH Biomarkers for Immuno-Oncology

11 - 12 MARCH Combination Immunotherapy

11 - 12 MARCH Bispecific Antibody Design and Applications

2020 Plenary Keynote Speakers

Stanley Riddell, MD, Scientific Director, Clinical Research, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine

Roy D. Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharpe & Dohme

Additional 2020 Featured Speakers

Renier Brentjens, MD, PhD, Director, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center; Professor, Pharmacology, Weill Cornell Graduate School of Medical Sciences

Sara Colombetti, PhD, Global Head of Oncology Discovery Pharmacology, Pharma Research and Early Development (pRED), Roche Innovation Center Zurich

George Coukos, Full Professor and Director, Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL); Director, Lausanne Branch, Ludwig Institute of Cancer Research Chief, Service of Immuno-Oncology, CHUV

Lindy Durrant, PhD, Professor of Cancer immunotherapy, University of Nottingham; CSO, Scancell Ltd

Gordon J. Freeman, PhD, Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

Maria Karasarides, PhD, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals

Roland Kontermann, PhD, Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart

Christophe-Le-Tourneau

Christophe Le Tourneau, MD, PhD, Senior Medical Oncologist, Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France

Jeanette Leusen, PhD, Associate Professor and Head Immunotherapy Group, Translational Immunology, University Medical Centre Utrecht

Wouter Scheper, PhD, Senior Postdoc, Molecular Oncology and Immunology, Netherlands Cancer Institute

Karoline Schjetne, PhD, Vice President Scientific Affairs, Vaccibody

Hans van der Vliet, MD, PhD, CSO, LAVA Therapeutics; Medical Oncologist, Amsterdam UMC